- World rank, all time
- #35,228 of 42,892
- Rank in France
- #1,925 of 2,321
- Research works
- 134 ▲ 104% vs 2013–17
- Citations
- 2.6k 19.7 per fractional work
- Top-10% rate
- 19.4% record average 16.5%
- Open access
- 42% world 28%
What does UniCancer Group specialise in?
Where its research is concentrated relative to its size: Medicine takes 3.8× the share of its output that it takes of world research.
- MedicineField · 34.3 works3.8×
- Health SciencesDomain · 35.4 works3.3×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Medicine, 3.8×. Every wedge is a field page.
- Medicine 3.8×
- Biochemistry, Genetics and Molecular Biology 2.7×
- Economics, Econometrics and Finance 1.9×
- Immunology and Microbiology 1.7×
- Mathematics 0.9×
- Health Professions 0.9×
- Decision Sciences 0.5×
- Physics and Astronomy 0.5×
- Neuroscience 0.2×
- Computer Science 0.1×
- Dentistry 0.1×
- Social Sciences 0.1×
- Psychology 0.0×
- Engineering 0.0×
Who are the top researchers at UniCancer Group?
Ranked on the composite score, Marta Jimenez, Anne‐Laure Martin and Jérôme Lemonnier lead among researchers whose main affiliation is UniCancer Group.
- 1 Marta Jimenez France · #143,432 worldwide 153 citations · 25 works
- 2 Anne‐Laure Martin France · #427,796 worldwide 97 citations · 18 works
- 3 Jérôme Lemonnier France · #759,143 worldwide 61 citations · 39 works
- 4 Sibille Everhard France · #1,604,030 worldwide 2 citations · 15 works
Which keywords describe research at UniCancer Group?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Chemotherapy, Breast Cancer, Quality of Life, Clinical Trials, Metastatic Breast Cancer, Immunotherapy, Clinical Practice Guidelines and Targeted Therapy.
- Psychosocial Interventions
- Anxiety
- Taxanes
- Health-related Quality of Life
- EGFR Mutations
- ALK Inhibitors
- PD-1 and PD-L1
- Cancer Survivorship
- Metastasis
- Breast Tumours
- Precision Medicine
- Palbociclib
- CDK4/6 Inhibitors
- Molecular Subtypes
- Prognostic Factors
- Neoadjuvant Therapy
- Radiotherapy
- Clinical Practice Guidelines
- Clinical Trials
- Breast Cancer
- Chemotherapy
- Quality of Life
- Metastatic Breast Cancer
- Immunotherapy
- Targeted Therapy
- Survival Analysis
- Tumor Microenvironment
- Biomarkers
- Gene Expression
- Genomic Profiling
- Prognostic Markers
- Treatment Response
- Genetic Mutations
- Immune Checkpoint Blockade
- Prostate Cancer
- Chemotherapy-Induced Peripheral Neuropathy
- Genomic Instability
- Molecular Characterization
- Treatment Guidelines
- Patient-Reported Outcomes
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Chemotherapy7▲ 22×19 topics
- Breast Cancer6▲ 52×10 topics
- Quality of Life5▲ 6.9×11 topics
- Clinical Trials4▲ 14×7 topics
- Metastatic Breast Cancer4▲ 165×2 topics
- Clinical Practice Guidelines4▲ 17×11 topics
- Immunotherapy4▲ 13×14 topics
- Radiotherapy4▲ 23×11 topics
- Targeted Therapy4▲ 40×5 topics
- Neoadjuvant Therapy4▲ 32×5 topics
- Survival Analysis3▲ 25×7 topics
- Prognostic Factors3▲ 15×12 topics
- Tumor Microenvironment3▲ 14×8 topics
- Molecular Subtypes3▲ 71×3 topics
- Biomarkers3▲ 8.5×9 topics
- CDK4/6 Inhibitors3▲ 228×1 topic
- Gene Expression3▲ 9.5×7 topics
- Palbociclib3▲ 228×1 topic
- Genomic Profiling3▲ 53×2 topics
- Precision Medicine3▲ 12×6 topics
- Prognostic Markers2▲ 49×3 topics
- Breast Tumours2▲ 103×1 topic
- Treatment Response2▲ 103×1 topic
- Metastasis2▲ 14×7 topics
- Genetic Mutations2▲ 9.5×8 topics
- Cancer Survivorship2▲ 53×2 topics
- Immune Checkpoint Blockade2▲ 35×1 topic
- PD-1 and PD-L12▲ 35×1 topic
- Prostate Cancer2▲ 29×3 topics
- ALK Inhibitors2▲ 57×1 topic
- Chemotherapy-Induced Peripheral Neuropathy2▲ 116×1 topic
- EGFR Mutations2▲ 57×1 topic
- Genomic Instability2▲ 33×3 topics
- Health-related Quality of Life2▲ 15×3 topics
- Molecular Characterization2▲ 21×4 topics
- Taxanes2▲ 116×1 topic
- Treatment Guidelines2▲ 17×2 topics
- Anxiety2▲ 7.2×3 topics
- Patient-Reported Outcomes2▲ 62×1 topic
- Psychosocial Interventions2▲ 62×1 topic
Which research topics does UniCancer Group publish most on?
By volume in 2022–2025: Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, Cancer Immunotherapy and Biomarkers and Cancer Treatment and Pharmacology.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 3 works
- 2 Breast Cancer Treatment Studies Cancer Research 2 works
- 3 Cancer Immunotherapy and Biomarkers Oncology 2 works
- 4 Cancer Treatment and Pharmacology Oncology 2 works
- 5 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 2 works
- 6 Cancer survivorship and care Oncology 2 works
- 7 Cancer Genomics and Diagnostics Cancer Research 1 works
- 8 Radiomics and Machine Learning in Medical Imaging Radiology, Nuclear Medicine and Imaging 1 works
- 9 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 1 works
- 10 Prostate Cancer Treatment and Research Pulmonary and Respiratory Medicine 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has UniCancer Group's research output changed?
Output in 2018–2022 was 104% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Paris
- Centre National de la Recherche Scientifique
- Inserm
- Sorbonne Université
- Université Paris Cité
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives
- Université Paris 1 Panthéon-Sorbonne
- Institut Pasteur
- Assistance Publique – Hôpitaux de Paris
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.